Kobayashi Pharmaceutical Co., a Japanese consumer health firm, is reportedly engaging in buyout talks estimated to be worth around $3.2 billion. This development comes after a major scandal in 2024 involving its red yeast rice supplements, which were linked to over 80 deaths due to citrinin contamination. The crisis triggered widespread product recalls and has severely impacted the company's sales and reputation. Despite having about $50 million in cash reserves and low debt, the financial strain from recall expenses exceeding $10 billion yen and lost market share has been substantial, leading to a 5% drop in net sales for the fiscal year ended March 2025 and a 15% decline in its healthcare segment. The company also slashed its dividend payouts by 50% in 2025.
The scandal led to significant leadership changes at Kobayashi Pharmaceutical. Its president and chairman were replaced in 2024, with a new CEO appointed who possesses extensive regulatory experience. The board was also restructured to include more independent directors focusing on compliance, and a new risk committee was established to oversee third-party ingredient testing. These measures were intended to restore investor confidence, but progress on transparency has been slow, and market reaction to the stock has remained cautious.
Regulatory scrutiny continues, with Japanese health authorities launching expanded investigations into the company's production facilities and supply chain practices as recently as March 2026, prompted by whistleblower reports of inadequate testing protocols. The company's admission in late 2025 of falsified safety data submissions further compounded its issues, potentially leading to billions of yen in compliance costs and fines. Competitors like Fancl Corp and Orihiro have capitalized on Kobayashi's struggles, gaining 10-15% market share in supplements. While its urinary health products, such as Urogin, saw an 8% growth, the core supplement line, which previously accounted for 25% of sales, faces indefinite suspension. This ongoing fallout underscores the high stakes of supplement safety in Asia and has implications for global consumer health supply chains, drawing parallels to FDA oversight in the US.
